Tavros Therapeutics is a precision oncology company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities.

Modular, scalable, and fast, the company’s next-generation, bi-directional CRISPR-based synthetic lethality discovery engine, EVOLVETM, can precisely and directly identify the paired genetic interactions that form the basis for breakthrough targets and first-in-class cancer drugs. Cutting-edge functional genomics and computational analysis accelerate the discovery of de-risked, druggable targets with the ultimate goal of improving patient outcomes, minimizing toxicity, and quickening development in defined patient subsets.

Tavros is leveraging its proprietary platform and synthetic lethal map to build a highly innovative pipeline of category-defining small-molecule drug candidates. In addition to developing drugs internally, Tavros has also built a strong foundation of partnerships and collaborations to expand our impact to patients.


Our leadership is comprised of successful serial entrepreneurs with deep expertise in functional genomics, tumor genetics and drug discovery.

Eoin McDonnell

CEO, Co-founder, Board Member

Nikki Heron


Kris Wood

Co-founder, Board Member

Assoc. Professor, Duke University
Robert Long

Board Member

Co-founder Piedmont Capital Investments

Investors & Partners

We are grateful for the support of our investors and relationships with collaborators and partners, which help accelerate our platform and program development.

Interested in working with Tavros? We are always excited to do great science through strategic collaborations. Contact us at info@tavrostx.com.